Euro Drug Pricing’s Tradeoffs May Limit Appeal In US image

Law360, September 8, 2016
Dani Kass, quoting W. Nicholson Price II (Academic Fellow Alumnus)


Read the Full Article

[...] Going forward, an influx of bills targeting drug prices could be introduced, but few are likely to pass, according to Joshua P. Cohen, a researcher at the Tufts Center for the Study of Drug Development.

“Congress as currently constituted is unlikely to pass a bill that goes against free market principles,” Cohen said in an email. “Furthermore, the vested interests are vehemently opposed to such legislation. As is often the case in political campaigns, most of what we hear is rhetoric with very little substance.”

But politicians may be all talk here, University of Michigan Law School professor Nicholson Price said, pointing to the lack of concrete change after Turing Pharmaceuticals Inc. and its founder Martin Shkreli raised the AIDS drug Daraprim from $13.50 to $750 per tablet without justification last year, drawing nationwide rage.

“We had this conversation with Daraprim, and it’s been around for a while in other contexts,” Price said. “Would it be lovely if this were the wakeup call moment, and somehow the market at large fixed everything? Yeah, but I’m a little pessimistic just given that fact that you could easily have told the same story about Daraprim, and it doesn’t seem to have made much of a difference.”

fda health care finance health law policy intellectual property international pharmaceuticals public health regulation w. nicholson price ii